Source: Annual Congress 2001 - Pulmonary thromboembolism and infections
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Obradovic (Sremska Kamenica, Yugoslavia). Activated protein C resistance in patients with pulmonary thromboembolism. Eur Respir J 2001; 16: Suppl. 31, 2608

Member's Comments

No comment yet.

Related content which might interest you: Impact of inherited activated protein C resistance on pulmonary artery pressure after acute episode of pulmonary thromboembolism Source: Eur Respir J 2001; 18: Suppl. 33, 380s Year: 2001 The relevant research of pulmonary thromboembolism and Protein C gene polymorphism Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease Year: 2010 C reactive protein level in pulmonary embolism. A marker of inflammatory processes in chronic thromboembolic pulmonary hypertension? Source: Eur Respir J 2007; 30: Suppl. 51, 602s Year: 2007 Inflammatory cell accumulation in pulmonary arteries is associated with systemic inflammation in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease Year: 2010 Variants  of genes related to cardiovascular disease in patients with pulmonary thromboembolism Source: International Congress 2018 – Pulmonary embolism: long-term sequelae and advances in therapies Year: 2018 Involvement of the pulmonary micro-vasculature in chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012 Homocysteine and serum-lipide levels in pulmonary thromboembolism Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease Year: 2008 Initial dual oral combination therapy prior to pulmonary endarterectomy (PEA) in patients with operable chronic thromboembolic pulmonary hypertension (CTEPH) and high preoperative pulmonary vascular resistance (PVR) Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020 The impact of immediate postoperative pulmonary vascular resistance on survival in patients with chronic thromboembolic pulmonary hypertension Source: Annual Congress 2009 - Pulmonary embolism Year: 2009 Btk (Bruton’s tyrosine kinase) in B cells is overexpressed in patients with idiopathic pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Effects of C-reactive protein on human pulmonary vascular cells in chronic thromboembolic pulmonary hypertension}, Source: Eur Respir J 2012; 40: 886-894 Year: 2012 Discrimination of acute and chronic pulmonary thromboembolism (PT) Source: Annual Congress 2007 - Pulmonary circulation Year: 2007 Chronic thromboembolic pulmonary hypertension (CTEPH) and coagulation defects: Before and after treatment Source: International Congress 2017 – PAH and CTEPH Year: 2017 Vascular wall remodeling in patients with chronic thromboembolic pulmonary hypertension: a role for C-reactive protein Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension Year: 2008 Survival in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2005; 26: Suppl. 49, 272s Year: 2005 Recurrent thromboembolism and pulmonary hypertension secondary to protein S deficiency (a case report) Source: Eur Respir J 2002; 20: Suppl. 38, 237s Year: 2002 Prevalence of chronic thromboembolic pulmonary hypertension (CTEPH) in patients after pulmonary embolism Source: International Congress 2018 – Clinical aspects of pulmonary hypertension Year: 2018 Frequency of chronic thromboembolic pulmonary hypertension screening after pulmonary embolism in cancer patients. Source: International Congress 2018 – Pulmonary embolism: long-term sequelae and advances in therapies Year: 2018 Differential expression of plasma microRNAs in chronic thromboembolic pulmonary hypertension and pulmonary embolism related to occult cancer Source: Virtual Congress 2021 – Pathogenesis and pathophysiology of pulmonary hypertension Year: 2021 A central role for nuclear factor of activated T cells (NFAT) in human pulmonary arterial hypertension Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006